Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes

Nicole L. Kallewaard, Davide Corti(Vir Biotechnology (Switzerland)), Patrick Collins(The Francis Crick Institute), Ursula Neu(The Francis Crick Institute), Josephine M. McAuliffe, Ebony Benjamin, Leslie Wachter-Rosati, Frances J. Palmer‐Hill, Andy Q. Yuan, P.A. Walker(The Francis Crick Institute), Matthias K. Vorlaender(The Francis Crick Institute), Siro Bianchi(Vir Biotechnology (Switzerland)), Barbara Guarino(Vir Biotechnology (Switzerland)), Anna De Marco(Vir Biotechnology (Switzerland)), Fabrizia Vanzetta(Vir Biotechnology (Switzerland)), Gloria Agatic(Vir Biotechnology (Switzerland)), Mathilde Foglierini(Università della Svizzera italiana), Debora Pinna(Università della Svizzera italiana), Blanca Fernandez‐Rodriguez(Università della Svizzera italiana), Alexander Fruehwirth(Università della Svizzera italiana), Chiara Silacci(Università della Svizzera italiana), R.W. Ogrodowicz(The Francis Crick Institute), Stephen R. Martin(The Francis Crick Institute), Federica Sallusto(Università della Svizzera italiana), JoAnn Suzich, Antonio Lanzavecchia(ETH Zurich), Qing Zhu(AstraZeneca (France)), S.J. Gamblin(The Francis Crick Institute), J.J. Skehel(The Francis Crick Institute)
Cited by 444Open Access
Full Text

Abstract

Influenza virus remains a threat because of its ability to evade vaccine-induced immune responses due to antigenic drift. Here, we describe the isolation, evolution, and structure of a broad-spectrum human monoclonal antibody (mAb), MEDI8852, effectively reacting with all influenza A hemagglutinin (HA) subtypes. MEDI8852 uses the heavy-chain VH6-1 gene and has higher potency and breadth when compared to other anti-stem antibodies. MEDI8852 is effective in mice and ferrets with a therapeutic window superior to that of oseltamivir. Crystallographic analysis of Fab alone or in complex with H5 or H7 HA proteins reveals that MEDI8852 binds through a coordinated movement of CDRs to a highly conserved epitope encompassing a hydrophobic groove in the fusion domain and a large portion of the fusion peptide, distinguishing it from other structurally characterized cross-reactive antibodies. The unprecedented breadth and potency of neutralization by MEDI8852 support its development as immunotherapy for influenza virus-infected humans.


Related Papers

No related papers found

Powered by citation graph analysis